Here is the kind request from Sanofi. The Survey is here and linked again at the bottom of the page. They would really appreciate your feedback! Thanks for considering it!
From Sanofi…
Below is a current scenario on which we would like your feed back. Please read through this explanation and kindly answer 5 short questions that follow.
People with Type 2 diabetes who have not previously used insulin can participate in a clinical study that is comparing three different types of (US) approved insulin. All medication is provided free of charge and all visits to the doctor responsible for their diabetes care are also free of charge.
The length of the study is 12 months with 4 visits. These visits are typical to what a diabetic patient would experience during a routine visit such as blood work and patient questionnaires.
An important part of this study is the collection of medical, pharmacy, and laboratory information for patients covered by a specific health insurance plan for the 12 months they are in the study. Collecting this information will help determine if there is an overall impact to the cost of diabetes care for patients after 6 months and after 12 months on the study. The information collected will be anonymous and collected only for the duration of the study.
The information collected will include things like how many times the patient visits the doctor or is admitted to the hospital, if laboratory test are performed, and if prescriptions are filled at the pharmacy.
Obtaining this information from the insurance company will not affect the patient’s insurance (copay or coverage) in any way, and it will not affect the current or future health care a patient will receive.
Patients that consent to have his/her insurance data released may withdraw their consent at any time without any effect on their insurance or medical care from their treating physician.
It will not identify patients individually.
Patient personal information will not be known and will not appear in any published data from this study. It will not be shared with other physicians.
This information will help the pharmaceutical company (sponsor of the study) get a well-rounded view of healthcare for people with Type 2 diabetes, along with the related costs and the value of different treatment options.